Understanding the benefit of metformin use in cancer treatment

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Dowling, Ryan J O ^a   Goodwin, Pamela J ^b   Stambolic, Vuk ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER RISK; CANCER THERAPY; COLON CANCER; COLORECTAL CANCER; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; HUMAN; HYPERINSULINEMIA; PROSTATE CANCER; SHORT SURVEY; DRUG COMBINATION; METHODOLOGY; NEOPLASM; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; METFORMIN; NEOPLASMS;

EID: 79953661884     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-33     Document Type: Short Survey

References (62)

1. Witters LA. The blooming of the French lilac. J Clin Invest 2001, 108:1105-1107. 209536, 11602616.
2. Hadden DR. Goat's rue - French lilac - Italian fitch - Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edinb 2005, 35:258-260.
3. Bailey CJ, Day C. Metformin: its botanical background. Pract Diab Int 2004, 21:115-117.
4. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996, 334:574-579. 10.1056/NEJM199602293340906, 8569826.
5. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?. Mol Cancer Ther 2010, 9:1092-1099. 10.1158/1535-7163.MCT-09-1186, 20442309.
6. Diamanti-Kandarakis E, Economou F, Palimeri S, Christakou C. Metformin in polycystic ovary syndrome. Ann N Y Acad Sci 1205:192-198. 10.1111/j.1749-6632.2010.05679.x, 20840272.
7. Rotella CM, Monami M, Mannucci E. Metformin beyond diabetes: new life for an old drug. Curr Diabetes Rev 2006, 2:307-315. 10.2174/157339906777950651, 18220635.
8. Dilman VM, Berstein LM, Ostroumova MN, Fedorov SN, Poroshina TE, Tsyrlina EV, Buslaeva VP, Semiglazov VF, Seleznev IK, Bobrov Y, Vasilyeva IA, Kondratjev VB, Nemirovsky VS, Nikiforov YF. Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology 1982, 39:13-19. 10.1159/000225596, 7058042.
9. Dilman VM, Berstein LM, Yevtushenko TP, Tsyrlina YV, Ostroumova MN, Bobrov Yu F, Revskoy S, Kovalenko IG, Simonov NN. Preliminary evidence on metabolic rehabilitation of cancer patients. Arch Geschwulstforsch 1988, 58:175-183.
10. Berstein LM. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond. Future Oncol 2010, 6:1313-1323. 10.2217/fon.10.87, 20799876.
11. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-1305. 10.1136/bmj.38415.708634.F7, 558205, 15849206.
12. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 2008, 8:501-505. 10.3816/CBC.2008.n.060, 19073504.
13. Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 2008, 15:833-839. 10.1677/ERC-08-0038, 18469156.
14. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005, 1:15-25. 10.1016/j.cmet.2004.12.003, 16054041.
15. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174. 209533, 11602624.
16. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000, 275:223-228. 10.1074/jbc.275.1.223, 10617608.
17. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004, 101:3329-3335. 10.1073/pnas.0308061100, 373461, 14985505.
18. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007, 8:774-785. 10.1038/nrm2249, 17712357.
19. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100:328-341. 10.1161/01.RES.0000256090.42690.05, 17307971.
20. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996, 81:4059-4067. 10.1210/jc.81.11.4059, 8923861.
21. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000, 49:2063-2069. 10.2337/diabetes.49.12.2063, 2995498, 11118008.
22. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646. 10.1126/science.1120781, 3074427, 16308421.
23. Hardie DG. The AMP-activated protein kinase pathway--new players upstream and downstream. J Cell Sci 2004, 117:5479-5487. 10.1242/jcs.01540, 15509864.
24. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009, 32:1620-1625. 10.2337/dc08-2175, 2732153, 19564453.
25. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010, 3:1451-1461. 10.1158/1940-6207.CAPR-10-0157, 20947488.
26. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010, 33:322-326. 10.2337/dc09-1380, 2809274, 19918015.
27. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009, 46:279-284. 10.1007/s00592-008-0083-2, 19082520.
28. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29:254-258. 10.2337/diacare.29.02.06.dc05-1558, 16443869.
29. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009, 27:3297-3302. 10.1200/JCO.2009.19.6410, 2736070, 19487376.
30. Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 76:1240-1244. 10.1016/j.urology.2010.03.059, 20627287.
31. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nakagama H, Nakajima A. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010, 3:1077-1083. 10.1158/1940-6207.CAPR-10-0186, 20810669.
32. Niraula S, Stambolic V, Dowling RJO, Ennis M, Chang MC, Done SJ, Hallak S, Hood N, Goodwin PJ. Clinical and biologic effects of metformin in early stage breast cancer. Cancer Res 2010, 70(24, Suppl):104s. Abs No. PD03-06.
33. Hadad SM, Dewar JA, Elseedawy E, Jordan LB, Purdie C, Bray SE, Thompson AM. Gene Signature of metformin actions on primary breast cancer within a window of opportunity randomized clinical trial. J Clin Oncol 2010, 28(Suppl):560.
34. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007, 67:10804-10812. 10.1158/0008-5472.CAN-07-2310, 18006825.
35. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006, 66:10269-10273. 10.1158/0008-5472.CAN-06-1500, 17062558.
36. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008, 27:3576-3586. 10.1038/sj.onc.1211024, 18212742.
37. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007, 67:6745-6752. 10.1158/0008-5472.CAN-06-4447, 17638885.
38. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol 116:92-98. 10.1016/j.ygyno.2009.09.024, 2789879, 19822355.
39. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, Micic D, Trajkovic V. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 2007, 64:1290-1302. 10.1007/s00018-007-7080-4, 17447005.
40. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008, 110:246-250. 10.1016/j.ygyno.2008.04.008, 18495226.
41. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009, 8:2031-2040. 10.4161/cc.8.13.8814, 19440038.
42. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009, 69:7507-7511. 10.1158/0008-5472.CAN-09-2994, 2756324, 19752085.
43. Vazquez-Martin A, Oliveras-Ferraros C, Barco SD, Martin-Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 2011,
44. Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B, Menendez JA. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010, 9:3807-3814. 10.4161/cc.9.18.13131, 20890129.
45. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, Franceschi C. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005, 40:685-693. 10.1016/j.exger.2005.07.007, 16125352.
46. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, Nakajima N, Nagashima Y, Wada K, Nakagama H, Nakajima A. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 2008, 99:2136-2141. 10.1111/j.1349-7006.2008.00933.x, 18803638.
47. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) 2010, 3:1066-1076. 10.1158/1940-6207.CAPR-10-0055, 20810672.
48. Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, Nozaki Y, Yoneda K, Fujita K, Yoneda M, Inamori M, Tomatsu A, Chihara T, Shimpo K, Nakagama H, Nakajima A. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 2010, 49:662-671. 10.1002/mc.20637, 20564343.
49. Belfiore A, Frasca F. IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:381-406. 10.1007/s10911-008-9099-z, 19016312.
50. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008, 114:23-37. 10.1080/13813450801969715, 18465356.
51. Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 2007, 106:39-47. 10.1007/s10549-006-9471-x, 17221153.
52. Ish-Shalom D, Christoffersen CT, Vorwerk P, Sacerdoti-Sierra N, Shymko RM, Naor D, De Meyts P. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997, 40(Suppl 2):S25-31. 10.1007/s001250051393, 9248698.
53. Basen-Engquist K, Chang M. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep 2011, 13:71-76. 10.1007/s11912-010-0139-7, 21080117.
54. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002, 20:42-51. 10.1200/JCO.20.1.42, 11773152.
55. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590. 10.1016/S0092-8674(03)00929-2, 14651849.
56. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480. 10.1038/sj.onc.1208304, 15608678.
57. Markman B, Atzori F, Perez-Garcia J, Tabernero J, Baselga J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2010, 21:683-691. 10.1093/annonc/mdp347, 19713247.
58. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009, 8:909-915. 10.4161/cc.8.6.7933, 19221498.
59. Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010, 11:390-401. 10.1016/j.cmet.2010.03.014, 20444419.
60. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010, 120:2355-2369. 10.1172/JCI40671, 2898585, 20577053.
61. Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 2011, 30:1174-1182. 10.1038/onc.2010.483, 21102522.
62. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011, 126:215-220. 10.1007/s10549-010-1224-1, 20976543.